MeMed said today that it won a $9.2 million contract from the Defense Threat Reduction Agency, a branch of the U.S. Dept. of Defense, for its diagnostic platform that distinguishes bacterial infections from viral infections.
The Israel-based company has developed a test to recognize the distinct human immune signatures of both bacterial and viral infections – an important medical distinction since the 2 ailments require different methods of treatment.
Get the full story at our sister site, Drug Delivery Business News.
The post MeMed wins $9.2m DoD deal for diagnostic device appeared first on MassDevice.
from MassDevice http://ift.tt/2oOYEdF
Cap comentari:
Publica un comentari a l'entrada